Author

Amelie Croset

Observed names: A. Croset, Amélie Croset

Institution: Molecular Partners (Switzerland)

Observed institutions: Université Paris-Sud, Centre National de la Recherche Scientifique, Inserm, Institut Pasteur, Molecular Partners (Switzerland), Intégrité du génome, ARN et cancer, Merck Serono S.A. (Switzerland), Ichnos Sciences (United States), Glenmark Pharmaceuticals (Switzerland), Muséum national d'Histoire naturelle, Institut Curie

ORCID: 0009-0003-1335-9653

Observed ORCID: 0009-0003-1335-9653

OpenAlex ID: A5082036851

Differences in the glycosylation of recombinant proteins expressed in HEK and CHO cells

2012 · Amelie Croset, Laurence Delafosse, et al. · Journal of Biotechnology · 229

Inhibition of DNA damage repair by artificial activation of PARP with siDNA

2013 · Amelie Croset, Fabrice P. Cordelières, et al. · Nucleic Acids Research · 47

PDF

PP2A1 Binding, Cell Transducing and Apoptotic Properties of Vpr77–92: A New Functional Domain of HIV-1 Vpr Proteins

2010 · Angélique N. Godet, Julien Guergnon, et al. · PLoS ONE · 35

PDF

Colorectal Cancer Metastasis: The DNA Repair Inhibitor Dbait Increases Sensitivity to Hyperthermia and Improves Efficacy of Radiofrequency Ablation

2013 · Flavien Devun, Julian Biau, et al. · Radiology · 28

The Combinatorial PP1-Binding Consensus Motif (R/K)x (0,1)V/IxFxx(R/K)x(R/K) Is a New Apoptotic Signature

2010 · Angélique N. Godet, Julien Guergnon, et al. · PLoS ONE · 19

PDF

The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell–Mediated Killing of AML Leukemic Stem Cells

2024 · Matteo Bianchi, Christian Reichen, et al. · Cancer Immunology Research · 17

PDF

ISB 1342: A first-in-class CD38 T cell engager for the treatment of relapsed refractory multiple myeloma.

2021 · Marie-Agnès Doucey, Blandine Pouleau, et al. · Journal of Clinical Oncology · 17

GBR1302: Effect of CD3-HER2, a bispecific T cell engager antibody, in trastuzumab-resistant cancers.

2018 · Jonathan Back, Martin Wermke, et al. · Journal of Clinical Oncology · 11

139 GBR1302: a BEAT® bispecific antibody for the treatment of HER2 positive cancers

2014 · A. Croset, J. Macoin, et al. · European Journal of Cancer · 8

ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of Relapsed Refractory Multiple Myeloma

2021 · Sammicheli Stefano, Camille Grandclement, et al. · Blood · 7

MP0533: A Multispecific Darpin CD3 Engager Targeting CD33, CD123, and CD70 for the Treatment of AML and MDS Designed to Selectively Target Leukemic Stem Cells

2022 · Matteo Bianchi, Christian Reichen, et al. · Blood · 5

Recommendations for Accurate Target Expression Evaluation by Quantitative Flow Cytometry

2025 · Tamara Lekishvili, Maxime Moulard, et al. · Cytometry Part A · 4

SiDNA and Other Tools for the Indirect Induction of DNA Damage Responses

2011 · Maria Quanz, Amelie Croset, et al. · InTech eBooks · 2

Abstract 3119: Next-generation multi-specific and conditionally activated CD3 Switch-DARPins with CD2 co-stimulation to tackle the current limitations of T cell engagers in solid tumors

2025 · Matteo Bianchi, Marco Franchini, et al. · Cancer Research · 1

Abstract 339: Development of 212Pb-based Radio-DARPin therapy (RDT) for the treatment of mesothelin (MSLN)-positive solid tumors

2025 · Stephan Wullschleger, Amal Saidi, et al. · Cancer Research · 1

Abstract 346: MP0712, the first anti-DLL3 212Pb radio-DARPin (RDT) candidate for targeted radiotherapy of small cell lung cancer (SCLC)

2025 · Amelie Croset, Amal Saidi, et al. · Cancer Research · 1

MP0621 (cKit x CD16a x CD47), a Multi-Specific Switch-Darpin with Conditional Blockade of CD47 Targeting Hematopoietic Stem Cells: Preclinical Evaluation of a Next-Generation Conditioning Agent for Stem Cell Transplantation

2024 · Alexander Link, Teresa Maria Frasconi, et al. · Blood · 1

PDF

A novel bispecific antibody for HER2+ breast cancer: The BEAT GBR 1302

2016 · Pierre Moretti, Julie Macoin, et al. · 1

Data from The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell–Mediated Killing of AML Leukemic Stem Cells